Target Price (Mid): ~$367Street Target: ~$283Potential Total Return: ~30%Annualized IRR: ~6% / yearWhat Happened?AbbVie (ABBV) presented primary Phase 2a results for ABBV-466, its investigational ...
AbbVie’s next-generation Crohn’s disease combination candidate has beaten Skyrizi in a midphase clinical trial. Skyrizi is a ...
AbbVie delivered a strong Q3 2025, with adjusted EPS of $1.86 (beating guidance by $0.10) and net revenues of $15.8B, up 8.4% operationally. Management raised full-year revenue and EPS guidance, ...
AbbVie’s ABBV key top-line drivers are its newer immunology medicines, Rinvoq and Skyrizi. Sales of both these drugs have effectively replaced the company’s flagship drug, Humira, which began facing ...
Welcome to the AbbVie First Quarter 2025 Earnings Conference Call. All participants will be able to listen only until the question and answer portion of this call. As a reminder, this call is being ...
AbbVie ABBV expects to return to robust revenue growth in 2025, just two years after losing U.S. exclusivity for its flagship drug, Humira. The drug, which went off-patent in January 2023, saw ...
CEO Robert Michael stated that "AbbVie's business continues to perform above our expectations. We delivered another excellent quarter, including strong financial results, pipeline advancement across ...
Johnson & Johnson’s Tremfya edged out AbbVie’s Skyrizi in the December rankings of the top 10 TV drug ad spenders, chalking up $56.4 million to Skyrizi's $42.3 million. (Martin Barraud/iStock/Getty ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results